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Conclusion: Many physicians reported use of class I AAD for the treatment
of post-MI patients with asymptomatic VPD in spite of the CAST findings.
This survey suggests that more effective methods of dissemination of clinical
trials results are needed.
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The Cost-Effectiveness of Pravastatin in Secondary
Prevention of Coronary Heart Disease
2:45
Care of Acute Myocardial Infarction by Non-invasive
and Invasive Cardiologists: Procedure Use, Cost,
and Outcome
Thomas G. Di Salvo, Sumita D. Paul, Conrad A. Smith, Michael!. Miyamoto,
Donald lIoyd-Jones, Kim A. Eagle, Patrick T. O'Gara Massachusetts General Hospital
and Harvard Medical School, Boston, MA
To determine if physician subspecialization influences practice style and
resource utilization, we prospectively studied 292 consecutive emergency
room admissions with MI under the care of noninvasive (NON, n = 213) or
invasive (INV, n = 791 cardiologists and compared the use of cardiac pro-
cedures, cost, and outcome. Results: Patient age, gender, CAD risk factors,
history of angina, MI, CHF, and prior cardiac catheterization, PTCA or CABG
were comparable. Presentation of MI. non-OIQ-wave MI, use of thrombolytic
therapy, peak CK, and EF did not differ. Procedures, cost, and length of stay
were as follows:
Talat Ashraf, Joel W. Hay, John R, Crouse, Michael H. Davidson, Curt D. Furberg,
Bertram Pitt, Ellison H. Wittels Emron, Inc., Warren, NJ: University ofSouthern
California, Los Angeles, CA
To determine the cost-effectiveness of pravastatin therapy in patients with
coronary heart disease, a projected risk model was developed that used
the results of the three-year, double blind, placebo controlled clinical trials:
Pravastatin Limitation ofAtherosclerosis in the Coronary Arteries (PLAC I) and
Pravastatin, Upids and Atherosclerosis in the Carotid Arteries (PLAC II). In
addition to measuring atherosclerotic progression, the PLAC studies eval-
uated four outcome variables: coronary heart disease death, non-coronary
heart disease death, fatal myocardial infarction, and non-fatal myocardial in-
farction in a patient population (mean age 60 years) with established coro-
nary heart disease and moderate low-density-lipoprotein cholesterol levels,
Pooled PLAC data analysis (n = 559) revealed a statistically significant (p <
0.05) difference in male non-fatal myocardial infarctions between the pravas-
tatin and placebo groups. The projected risk model utilized Framingham data
to project the risk of mortality 10 years post myocardial infarction. Markov
Process was used to estimate the life-years saved and cost. All costs and
benefits were discounted by 5%, Results are presented in the table below:
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Cost per Life-Year Saved
$19,082
$14,022
$10,630
Clinical and Economic Studies of PTCA
Patient Risk Profile
Male with CHD + 1Additional Risk Factor
Male with CHD + 2 Additional Risk Factors
Male with CHD + 3 Additional Risk Factors
Based on this model, pravastatin monotherapy in secondary prevention of
coronary heart disease has a cost-effectiveness ratio comparable to some of
the widely accepted medical interventions such as breast cancer screening,
$21,700, hydrochlorothiazide in the treatment of hypertension, $16,400, and
pneumococcal vaccine, $12,000.
Influence of Platelet GP lib/ilia Receptor
Inhibition with c7E3 on the Sequelae of
Dissection During Percutaneous Coronary
Revascularization
A. Michael Lincoff, Eric J. Topol, Robert M, Califf, Harlan F. Weisman, Nancy
M. Wildermann, Stephen G. Ellis. The Cleveland Clinic Foundation, Cleveland, OH;
Duke University. Durham, NC
The EPIC Trial tested the efficacy of the c7E3 monoclonal antibody to the
platelet GP IIblllla receptor in preventing ischemic events during "high-risk"
PTCA or atherectomy by randomizing 2099 pts to receive placebo (PL), c7E3
bolus (BO), or c7E3 bolus + 12 hr infusion (BO + IN). BO + IN of c7E3 pro-
duced a 35% reduction in the 30-day composite primary endpoint (death, MI,
urgent CABG, or re-PTCA) from 12.8% to 8.3% (p = 0,009) compared with
placebo. Although c7E3 would not be expected to prevent the mechanical
complication of coronary dissection, this agent may limit subsequent throm-
bus formation at dissection sites and thereby prevent progression to overt
closure, embolization, or ischemic clinical events.
The influence of c7E3 on adverse sequelae among pts who sustained dis-
section during EPIC was therefore investigated. Moderate (2-10 mm) or long
I> 10 mm) dissections, as determined by Angiographic Core Laboratory anal-
ysis, occurred in 40.1 %, 39,3%, and 42.5% of pts randomized to PL, BO, or
BO + IN, respectively.
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NON INV p-value
Thall Ell (%) 45 36 NS
Catheterization (%) 59 67 NS
CABG (all pts, %) 13 12 NS
PTCA (3VD, %) 17 35 NS
PTCA (1 or 2-VD, %) 39 60 <0.05
Total hospital days 14 17 <005
ICU days 31 5.4 <001
Hospital costs 1$) 19,400 25,500 0.01
Background: High plasma homocysteine concentration is a significant risk
factor for premature vascular disease in men, but the role in determining
coronary disease risk in women remains unclear.
Methods: Risk factors, including hypertension, hypercholesterolemia,
smoking, and diabetes were recorded in 228 patients (175 men, 53 women)
with angiographically documented coronary disease (2:70% stenosis of at
least one major coronary vessel), and 223 healthy controls (181 men, 42
women), Fasting total plasma homocysteine was measured in all subjects.
A high homocysteine concentrations was defined as a level greater than the
80th percentile, adjusted for gender.
Results: In univariate analysis, homocysteine correlated with age, but not
smoking, hypertension or hypercholesterolemia. Homocysteine values and
odds ratios based upon multivariate analysis were:
There were no differences between groups in the incidence of post-
MI complications (shock, pulmonary edema, post-MI angina, VTNF) or re-
versible thallium perfusion defects. Overall, 61 % of patients underwent car-
diac catheterization; there were an equal number of patients with 1, 2, and
3-vessel CAD in each group. Multivariate predictors of PTCA in patients with
1 or 2-vessel CAD were previous PTCA, Q-wave MI, and care by INV. Out-
come: In-hospital reinfarction and mortality (8.7% vs 12.7%) did not differ;
during median 12-month follow-up (96% of pts), reinfarction and mortality
(11.3% vs 10.3%) were similar, ConClusion: In this pilot study, subspecial-
ization impacted upon the cost of care of MI and led to increased PTCA in
patients with 1 or 2-vessel CAD; larger studies are needed to determine the
influence of subspecialization on long-term clinical outcomes.
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High Homocysteine Concentrations: An Independent
Risk Factor for Coronary Atherosclerosis in Women
Ellen Mayer, Dave Miller, Anjun Gupta, Steven E. Nissen, Donald W. Jacobsen,
Ralph Green, Kandice Kottke Marchant, Killian Robinson. The Cleveland Clinic
FoundaD'on, Cleveland, Ohio
Abrupt Closure 13% 7% 10% 0,080
Embolization < 1% 1% 1% 0.693
Primary Composite Endpoint 17% 12% 10% 0025
Death 3% 1% 1% 0.510
Myocardial Infarction 12% 6% 7% 0013
Emergency Re-PTCA 6% 5% 1% 0002
Emergency CABG 5% 3% 3% 0.350
Women Men
Patients Controls Patients Controls
Age 62 ± 12' 53 ± 10 61 ± 11' 51 ± 10
Homocysteine Levell/lmol!L) 127 ± 4.4' 102 ± 4.9 13.1 ± 4.3' 11.3 ± 30
Percent High Homocysteine 55,t 20 35' 20
Odds Ratio 3.2' NA 1.9' NA
Confidence Interval 1.2-£.4 NA 11-33 NA
* p < 0.01 V$ controls; t p < 0.05 vs male patients
Event PL (N = 278) BO IN = 273) BO + IN IN ~ 301) p-value
Conclusions: Mean homocysteine concentrations are higher in women
with coronary disease than age and sex matched controls. High homocys-
teine levels are more frequently seen in women than men and confer an
independent three-fold incremental risk of CAD.
Although c7E3 did not significantly diminish the risk of abrupt closure or
embolization among pts with moderate or long coronary dissections, potent
reduction in the incidences of MI and emergency repeat revascularization
may reflect ultimate stabilization of disrupted vascular segments during the
lACC February 1995 ABSTRACTS 391A
post-procedural period. Further study is warranted to investigate a strategy
of administration of c7E3 after coronary dissection has occurred.
were examined with univariate followed by stepwise multivariate regression
analysis.
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Heparin Dosing Nomogram
Correlates of Acute Myocardial Infarction (AMI)
After Successful Coronary Angloplasty (PTCA)
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Patient Weight (kg)
Univariate Multivariate
critical value p-value critical value p·value
Age 0034 ns
Weight -2.15 0.033 -2925 <0.001
Female Gender 121 0.34
Unstable Angina -2.04 0.043 -0.069 ns
Pre-procedural IV Heparin -538 <0.001 -2.39 0023
Heparin Dose 635 <0.001 8.95 <0.001
95
90
100 --.-------,
Chi SO ODDS Ratio p Value
Previous MI 37 149 <0.0001
Angina Class III-IV 20 1.17 <0.0001
Diabetes 13 146 <0.0001
Multivessel CAD 11 1.26 0.001
Age 8 0.98 0.004
CHF 5 134 0024
Conclusions: Patient weight, pre-procedural IV heparin therapy, and hep-
arin dose were significant independent predictors of the ACT achieved, Pre-
procedural intravenous heparin significantly increased the heparin dose re-
quired to achieve the target ACT, suggesting the development of tolerance
to heparin. Similarly, patients with unstable angina required significantly
more heparin to achieve the target ACT Recognition of these factors allows
patient-specific heparin dosing during angioplasty. A nomogram for patients
receiving pre-procedural heparin therapy, for example, shows the relation-
ship between patient weight. heparin dose, and the expected target ACT.
In long term follow up after successful angioplasty, the presence of these
co-morbid illnesses may help in identifying the patients at higher risk of hav-
ing AMI after successful angioplasty, This risk stratification strategy may in-
fluence survival after angioplasty.
Rizwan A Karatela, William S. Weintraub, John S, Douglas Jr, Spencer B. King III.
Emory University School of Medicine, Atlanta, GA
To identify the factors predicting AMI after PTCAwe studied 10,772 patients
who had successful PTCA at our institution. 880 patients had AMI following
discharge while 8.754 patients remained AMI free during long term follow up
after successful uncomplicated PTCA While there was no difference in the 5
year freedom from AMI based on sex, presence of hypertension or LVH, the
freedom from AMI was lower in patients with previous MI (84% vs 91 %, P
= < 0.0001), diabetes (84% vs 90%, p = < 0,0001). angina class III-IV (87%
vs 91 %, P ~ < 0.0001), and CHF (85% vs 89%, P = 0.014). The multivariate
correlates of AM I were:
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A New Low Cost Protocol for Elective PTCA
Preconditioning Human Myocardium -
Reduced Hypoxanthine Production During PTCA
Patient-Specific Heparin Dosing During
Angioplasty
Pts LOS Campi Costs ($) Savings
Lab Room Total
Prepath 819 2.1 1.6% 2,670 825 3.495
Path "p;' 115 104 0.9% 2,582 590 3,172 9.2%
Path "B" 227 1.28 0.9% 2,654 643 3,297 5.7%
Mark Nootens, Joseph Condon, Greg Elsner, Brenda Erner, Ronald Landin,
Charles Orr, James Hermiller, Cass Pinkerton, Thomas Linnemeier. The Indiana
Heart Institute, Indianapolis, IN
In order to curb costs, 2 protocols for elective PTCA were developed. Path
"/Ji' pts had sheath removal ASAP following PTCA (when ACT < 1501 and
discharge after 12 hrs IV heparin. Path "B" pts had overnight heparin with
sheath removal the following morning. "/Ji' pts had no venous sheath, type
and screen, IV NTG or labs except PH drawn post PTCA. "B" pts had a
venous sheath, type and screen, IV NTG and labs drawn post PTCA (lytes,
BUN/creat, CPKx3). Unstable angina, acute MI, staged PTCA or stents were
excluded. "/Ji' or "B" was used for elective PTCA, at the discretion of the an-
giographer, from 7/93-7/94 and compared to prior elective PTCA, 7/92-7/93
(prepathl
Conclusion: In elective PTCA costs are reduced safely by discharge the
next day (path "B") and further in selected pts by using a new low cost pro-
tocol (path "/Ji'). Additional savings might be appreciated if these pts were
observed in a less intense setting after sheath removal.
LOS = length of stay (days), Campi = death, MI, CVA or hematoma requiring vascular
repair or transfusion. Lab = cath lab. supplies and blood work costs, Room = PTCA unit
and telemetry costs
Hypoxanthine release is reduced after second and third prolonged balloon
inflations when compared to the first shorter inflation reflecting an adaptive
response of the myocardium to ischaemia. These results show metabolic
evidence for preconditioning in the human myocardium.
Hypoxanthine
(flmolesAitre of blood) -001 ± 0.37 -3.41 ± 2.05 -1.54 ± 0.64 -242 ± 0.56
Nigel Jepson, Kameljit Kalsl 1, Richard Cowell, Vincent Paul, Charles Iisley,
Anne-Marie Seymour 1. Dept. of Cardiology, NHU, Harefield Hospital, Middlesex, UK.;
1 Dept of Cardiothoracic Surgery. NHU, Harefield Hospital, Middlesex, UK.
Brief episodes of myocardial ischaemia and reperfusion protect against sub-
sequent prolonged ischaemic insults. This adaptive response termed pre-
conditioning has been observed with successive coronary occlusions at
PTCA based on recordings of anginal intensity and ECG changes. The aim of
this study was to evaluate myocardial release of Hypoxanthine (HXllan ATP
catabolite and a sensitive marker of ischaemia) in coronary sinus blood im-
mediately after successive balloon inflations. Nine male patients mean age
50 ± 2.1 with isolated left anterior descending artery stenoses and normal
left ventricular function were studied. Collateral channels filling diseased ar-
terial segment were absent on the diagnostic angiogram, PTCA consisted
of three balloon inflations, durations of which were: (1) 60-90 seconds, (21
90-180 seconds, (3) 180-300 seconds with 5 minutes of intervening reper-
fusion between each. Paired aortic and coronary sinus blood samples were
taken immediately after each deflation and deproteinized with 1.3 M HCI04
and neutralized supernatant fractions analysed by HPLC for HX content. The
arteriovenous differences (mean ± SEM) were:
William B. Hillegass, Brigit1a C. Brott. Eric B. Haura, Robert A. Harrington, Harry
R. Phillips, Richard S. Stack, Robert M. Califf. Duke Hospital, Durham, NC
The risk of ischemic events and bleeding complications during angioplasty
is related to the intensity of heparin anticoagulation as monitored by the
activated clotting time (ACT). Data on patient characteristics that affect the
dosing of heparin during angioplasty to achieve a desired target ACT is lim-
ited. The Hemochron ACT was measured 10 minutes after a heparin bolus
in 438 non-emergency angioplasty patients. The influence of heparin dose,
patient age, weight. gender, presenting diagnosis, and pre-procedural con-
tinuous intravenous heparin use on the intensity of anticoagulation achieved
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